论文部分内容阅读
为了解原发性肝癌患者经肝动脉化疗栓塞（ＴＡＥ）治疗后免疫功能状态，我们检测２９例原发性肝癌患者血液可溶性白细胞介素２受体（ｓＩＬ２Ｒ）、辅助Ｔ淋巴细胞、抑制Ｔ淋巴细胞。发现原发性肝癌患者Ｔｈ细胞显著下降，Ｐ＜０．０５。ｓＩＬ２Ｒ、Ｔｓ细胞比健康对照组明显增高，Ｐ＜０．０５；ＴＡＥ治疗后原发性肝癌患者Ｔｈ细胞明显增高，Ｐ＜０．０５，ｓＩＬ２Ｒ、Ｔｓ细胞显著降低Ｐ＜０．０５。测定原发性肝癌患者血液中ｓＩＬ２Ｒ、Ｔｈ、Ｔｓ细胞对判断患者免疫功能状态、疗效、预后有一定的价值。
To understand the immune function of hepatocellular carcinoma patients treated with transcatheter arterial chemoembolization (TAE), we examined the serum soluble interleukin 2 receptor (sIL2R), helper T lymphocytes, and suppressor T lymphocytes in 29 patients with primary liver cancer. cell. The Th cells in patients with primary liver cancer were significantly decreased, P<0.05. The sIL2R and Ts cells were significantly higher than those in the healthy control group (P<0.05). After treatment with TAE, the Th cells in the primary liver cancer patients were significantly higher (P<0.05), and the sIL2R and Ts cells were significantly lower (P<0.05). The determination of sIL2R, Th and Ts cells in the blood of patients with primary liver cancer has certain value in judging the patient’s immune function status, efficacy, and prognosis.